Anixa Biosciences Inc

Anixa is headquartered in the United States and its business is primarily U.S.-centric from a research, clinical, and corporate standpoint. The company’s development work relies on collaborations with U.S.-based research institutions, including Moffitt Cancer Center and Cleveland Clinic, and subcontractors supporting those programs. Because the company is pre-commercial, it does not disclose meaningful country-level revenue from its core oncology pipeline, and it reported no revenue in fiscal 2025 or 2024. Geographic exposure is therefore driven more by where trials, collaborators, regulators, and future commercialization partners are located than by current sales mix.

The company faces the classic risks of an early-stage biotech: no product revenue, uncertain clinical outcomes, and a long path to regulatory approval. Its programs are novel, so even positive preclinical or early human data may not translate into successful late-stage results or market acceptance. Anixa also depends on third parties for trials, manufacturing, and commercialization, which creates execution risk and reduces control over timing and cost. In addition, the company may need more capital, and any future financing could be unavailable or dilutive; broader biotech competition, intellectual property challenges, and product liability exposure add further uncertainty.